DDInter380 DDInter1747
A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Cimetidine {u} (Compound) treats {v} (Disease) obesity
Cimetidine {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
Cimetidine {u} (Compound) is included by {v} (Pharmacologic Class) Histamine H2 Receptor Antagonists
Cimetidine {u} (Compound) downregulates {v} (Gene) COTL1
Cimetidine {u} (Compound) causes {v} (Side Effect) Flatulence
Cimetidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Quinestrol
Cimetidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Indomethacin
Cimetidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Labetalol
Cimetidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duloxetine
Cimetidine {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Cimetidine (Compound) treats obesity (Disease)
Cimetidine (Compound) binds CYP3A7-CYP3A51P (Gene)
Cimetidine (Compound) is included by Histamine H2 Receptor Antagonists (Pharmacologic Class)
Cimetidine (Compound) downregulates COTL1 (Gene)
Cimetidine (Compound) causes Flatulence (Side Effect)
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Quinestrol
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Indomethacin
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Labetalol
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine
Cimetidine may lead to a major life threatening interaction when taken with Dasatinib